Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

被引：16
作者：
Katz, Matthew H. G.
Varadhachary, Gauri R.
Bauer, Todd W.
Acquavella, Nicolas
Merchant, Nipun B.
Le, Tri Minh
Javle, Milind M.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Hozaeel, Wael
    Pauligk, Claudia
    Homann, Nils
    Luley, Kim
    Kraus, Thomas Werner
    Trojan, Jorg
    Bechstein, Wolf O.
    Grimm, Kersten
    Heise, Bettina
    Schmiegel, Wolff
    Pink, Daniel
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Al-Batran, Salah-Eddin
    Reichart, Alexander
    Bankstahl, Ulli Simone
    Pauligk, Claudia
    Kraus, Thomas Werner
    Bechstein, Wolf Otto
    Trojan, Jorg
    Behrend, Matthias
    Potenberg, Jochem
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Alber, Karsten
    Siegler, Gabriele Margareta
    Hozaeel, Wael
    Goetze, Thorsten Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
    Uboha, Nataliya Volodymyrivna
    Eickhoff, Jens C.
    Maloney, James D.
    McCarthy, Daniel
    DeCamp, Malcolm
    Deming, Dustin A.
    LoConte, Noelle K.
    Matkowskyj, Kristina A.
    Patel, Monica Arun
    Hurst, Newton
    Kratz, Jeremy D.
    Lubner, Sam Joseph
    Bassetti, Michael Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer
    Kubota, Kensuke
    Sato, Takamitsu
    Watanabe, Seitaro
    Hosono, Kunihiro
    Kobayashi, Noritoshi
    Mori, Ryutaro
    Taniguchi, Koichi
    Matsuyama, Ryusei
    Endo, Itaru
    Nakajima, Atsushi
    DIGESTIVE ENDOSCOPY, 2014, 26 (01) : 77 - 86
  • [45] A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
    Fuyuhiko Motoi
    Sohei Satoi
    Goro Honda
    Keita Wada
    Hiroyuki Shinchi
    Ippei Matsumoto
    Masayuki Sho
    Akihiko Tsuchida
    Michiaki Unno
    Journal of Gastroenterology, 2019, 54 : 194 - 203
  • [46] A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
    Motoi, Fuyuhiko
    Satoi, Sohei
    Honda, Goro
    Wada, Keita
    Shinchi, Hiroyuki
    Matsumoto, Ippei
    Sho, Masayuki
    Tsuchida, Akihiko
    Unno, Michiaki
    Kurata, M.
    Yanagimoto, H.
    Toyama, H.
    Nagakawa, Y.
    Maemura, K.
    Mataki, Y.
    Akahori, T.
    Kinoshita, S.
    Terashima, H.
    Horiguchi, A.
    Ohtsuka, Y.
    Nanashima, A.
    Kanemitsu, K.
    Ohigashi, H.
    Tani, M.
    Takahara, T.
    Shiomi, H.
    Endo, I.
    Suzuki, H.
    Rikiyama, T.
    Ikoma, H.
    Yasunaga, M.
    Nakamura, K.
    Egawa, S.
    Katayose, Y.
    Nakagawa, K.
    Okada, K.
    Ottomo, S.
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (02) : 194 - 203
  • [47] A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement
    Ikenaga, Naoki
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Nakata, Kohei
    Adachi, Tomohiko
    Eguchi, Susumu
    Nishihara, Kazuyoshi
    Inomata, Masafumi
    Kurahara, Hiroshi
    Hisaka, Toru
    Baba, Hideo
    Nagano, Hiroaki
    Ueki, Toshiharu
    Noshiro, Hirokazu
    Tokunaga, Shoji
    Ishigami, Kousei
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (01) : 193 - 202
  • [48] A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers
    Ko, A. H.
    Noel, M.
    Chao, J.
    Sohal, D.
    Crow, M.
    Oberstein, P. E.
    Scott, A.
    Mcree, A.
    Lima, C. Rocha
    Fong, L.
    Keenan, B.
    Filbert, E.
    Hsu, F. J.
    Shankaran, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1111 - S1111
  • [49] Efficacy and safety of neoadjuvant therapy with stereotactic body radiation therapy followed by nab-paclitaxel/gemcitabine plus camrelizumab for resectable, borderline resectable and locally advanced pancreatic cancer: Preliminary results.
    Xue, Jun
    Hu, Yue
    Gou, ShanMiao
    Yin, Tao
    Li, Xin
    Wang, Jing
    Liu, Hongli
    Yang, Ming
    Ma, Hong
    Hu, Jianli
    Lin, Zhenyu
    Li, Pindong
    Wu, Heshui
    Zhang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16227 - E16227
  • [50] A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.
    Hall, William Adrian
    Tsai, Susan
    Banerjee, Anjishnu
    George, Ben
    Ritch, Paul S.
    Thomas, James P.
    Paulson, Eric
    Christians, Kathleen K.
    Clarke, Callisia
    Dua, Kulwinder
    Khan, Abdul H.
    Knechtges, Paul
    Hagen, Catherine E.
    Evans, Douglas B.
    Erickson, Beth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345